The clinical evidence, shared by BioArctic’s partner Eisai, highlights that a once-weekly 500 mg dose of the subcutaneous autoinjector (SC-AI) achieves drug exposure nearly identical to the standard bi-weekly intravenous regimen. Researchers noted a bioequivalence ratio of 104%, maintaining stable profiles across various patient body weights. This consistency suggests that clinical outcomes, such as amyloid clearance and cognitive stability, depend on total drug exposure rather than the specific delivery method.
New clinical data suggests subcutaneous Leqembi matches IV efficacy
Data presented at the 2026 Alzheimer's Association International Conference in London confirms that the subcutaneous autoinjector formulation of Leqembi provides comparable efficacy and safety to traditional intravenous administration. The findings suggest a potential shift toward more flexible, at-home treatment pathways for patients living with early-stage Alzheimer's disease.
Beyond technical equivalence, the data addresses practical needs in long-term care management. Real-world insights from two major U.S. treatment centers indicated that patients transitioning to or initiating with the autoinjector reported high satisfaction levels, often exceeding 90%. Clinically, patients observed slower cognitive decline over 36 months compared to natural history cohorts. The subcutaneous option also offers logistical flexibility, allowing for delayed dosing if a scheduled injection is missed. Safety profiles remained consistent with intravenous therapy, with low rates of immunogenicity and manageable injection-site reactions, reinforcing the potential for broader adoption in diverse healthcare settings.
Comments (0)
No comments yet. Be the first!